Detection of equine arteritis virus (EAV) by polymerase chain reaction (PCR) and differentiation of EAV strains by restriction enzyme analysis of PCR products

Brief Report

K. Sekiguchi1, S. Sugita1, Y. Fukunaga1, T. Kondo1, R. Wada1, M. Kamada1, and S. Yamaguchi2

1Epizootic Research Station, Equine Research Institute, Japan Racing Association, Tochigi-Ken, 2Fourth Laboratory of Virology, Second Research Division, National Institute of Animal Health, Ibaraki-Ken, Japan

Accepted March 31, 1995

Summary. A polymerase chain reaction (PCR) based assay capable of detecting and differentiating seven strains of equine arteritis virus (EAV) from around the world was developed. The primers for the PCR were chosen from the ORF 6 gene encoding the unglycosylated membrane protein (M). Viral RNA from cell culture fluids infected with each of the seven EAV strains and RNA from the live vaccine, Arvac, was detected by PCR using four sets of primers. The sensitivity of detection was increased from 100 to 1000 times by performing nested PCR enabling the detection of RNA at a level of 0.5–5 PFU. Differentiation among the virus strains and the live vaccine was achieved by cutting the PCR-amplified products from three sets of primers with six restriction endonucleases. Using this procedure it was possible to distinguish among the seven EAV strains used.

The equine arteritis virus (EAV) has been classified as a member of the Togaviridae family [22, 24]. However, recently EAV has been found to resemble the coronavirus and torovirus in its genome organization and gene expression strategy [7], yet differing from them in virion genome size and virion morphology. Therefore EAV may be a member of a recently proposed new family of viruses, the Arteriviridae, consisting of the lactate dehydrogenase-elevating virus, porcine reproductive and respiratory syndrome virus, and simian hemorrhagic fever virus [7, 21]. The clinical signs of equine viral arteritis are very variable and subclinical infections are the most common sequel [12]. To date a single serotype has been recognized, and no major antigenic variation has been demonstrated among EAV isolated from disparate chronological and geographic origins [18]. Murphy et al. showed high
levels of genomic heterogeneity among isolates of EAV through oligonucleotide fingerprint comparisons [19, 20]. We determined the nucleotide sequence of ORF 6, which encodes the unglycosylated membrane protein (M), from several strains from around the world, and showed many genetic variations among the strains in spite of limited antigenic variations [23]. The objective of this study was to detect each of the EAV strains using PCR, and to differentiate the strains through restriction enzyme analysis of their PCR products, based on the M protein nucleotide sequence data of the strains, together with those of the Bucyrus [7] and modified Bucyrus strain [25].

EAV strains used in this study were as follows: Bucyrus (Ohio) [8], modified Bucyrus [9, 14], Red Mile (Kentucky) [15], 84 KY-A1 (Kentucky) [19], Wroclaw-2 (Poland) [11], Bibuna (Switzerland) [2] and Vienna (Austria) [3]. In addition, a modified live virus vaccine (Arvac) was used. All strains of EAV were propagated in an RK13 rabbit kidney cell line. RNA was extracted from 250 μl of culture fluid with 500 μl of RNAzol B (Biotecx Laboratories, Inc.). RNA was precipitated with isopropanol, using 2 μl of ethachinmate (Nippon gene Co., Japan) as a carrier. The RNA pellet was dissolved in 30 μl of TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). Six primers were selected from the coding region for the M protein. The structure of the EAV genome, the location of the primer pairs and the restriction sites used are shown in Fig. 1. Upper primer; M1, 5'-CTGAGGTATGGGAGC-

Fig. 1. Schematic representation of the EAV genome, and the locations of the PCR primers and restriction enzyme cleavage sites in the PCR products. The boxes with numbers indicate ORFs. The filled boxes indicate the 5' leader sequence. The open boxes indicate primers.
CATAG-3’ (identical to nucleotides 11895–11914 [7]). M6, 5’-TTAGCAGCCTATATTGTTTGTTGTT-3’ (identical to nucleotides 12052–12074). M9, 5’-TATGCTTTTGTGCTTTTGCTGC-3’ (identical to nucleotides 12103–12125). Lower primer; M14, 5’-GCAGCACAAGCAACAAAGC-3’ (complementary to nucleotides 12125–12106). M8, 5’-CAAACCTGCCGTGCCGACCCTGC-3’ (complementary to nucleotides 12298–12300). M10, 5’-GGCCTGCGGACGTGATCG-3’ (complementary to nucleotides 12343–12326). Reverse transcription and PCR were performed in a final volume of 20 μl containing 3 μl of RNA using a GeneAmp RNA PCR kit (Perkin-Elmer-Cetus Co.) according to the protocol of the supplier. The tube was incubated at 42 °C for 15 min, at 94 °C for 5 min, and at 5 °C for 5 min. PCR was carried out in a final volume of 100 μl containing 20 μl of cDNA, 4 μl of MgCl₂ (25 mM), 2 μl of 10 x PCR buffer, 1 μl of upper stream primer (20 μM), 0.5 μl of AmpliTaq DNA polymerase (5 U). The mixture was incubated at 94 °C for 2 min, followed by 35 cycles of denaturation (94 °C for 1 min) and annealing (60 °C for 1 min), and a final extension (60 °C for 7 min). Double nested PCR amplification was carried out using the external primer M1–M10 and various sets of inner primers. The second round amplification was carried out in a 50 μl reaction mixture containing 5 μl of 10 x PCR buffer, 0.2 U/μl of Taq polymerase, 2 mM of MgCl₂, 0.2 mM of each dNTP, 0.2 μM of each inner primer and 1 μl of the first round PCR product. Denaturation and annealing consisted of 35 cycles 94 °C for 1 min, and 60 °C for 1 min, respectively, followed by a 7 min extension at 60 °C.

Using the primer pairs of M1–M10, M1–M14, M6–M8, or M9–M10, RNA from each of the strains and the live vaccine was equally and efficiently amplified producing a band of 449 bp, 231 bp, 247 bp, and 241 bp, respectively (Fig. 2). However, there was a single base mismatch in the M9 and M14 regions of the modified Bucyrus strain, in M6 of the Vienna strain, in M8 of the Bibuna and Vienna strains, and in M10 of the Bibuna strain. These mismatches were single internal mismatches, which probably had no significant effect on the PCR product yield. The mismatches in primer M9, M14, M6, and M10 were C:A (primer: template), A:C, C:T, and G:T, respectively. These mismatches were efficiently amplified even when located at the 3’ end of the primer [13]. The sensitivity of PCR for detecting EAV was determined by using serial ten-fold dilutions of infected cell fluid with a modified Bucyrus strain (2 × 10⁷ PFU/ml). The first round PCR using the M1–M10 primer pair generated a faint though visible 449 bp product at a dilution level of 10⁻³, corresponding to about 500 PFU (Fig. 3A). When the PCR product obtained from the first round PCR was reamplified with one of the three sets of inner primers M1–M14, M6–M8, or M9–M10, all of the respective 231 bp, 247 bp and 241 bp products were detected at a 10⁻⁶ dilution level of cell fluid (Fig. 3B). The results showed that reamplification with the nested or hemi-nested primers increased sensitivity by at least 100–1000 times, enabling us to detect at a level of 0.5–5 PFU. However, amplified DNA was not detected when the first round PCR product was amplified using an equine herpesvirus (EHV)-1 gC primer, even though a 712 bp product of EHV was produced using the primer in the presence of an EHV genome (Fig. 3B). The genome of EHV and equine influenza virus yielded no amplification band using the EAV primer pairs.
Fig. 2. Analysis of PCR amplification products derived from viral RNA extracted from culture infected with the EAV strains and from the live vaccine, using the four primer pairs: A M1-M10, B M1-M14, C M6-M8, D M9-M10. Five μl of product were electrophoresed through a 2% agarose gel in a TAE buffer (40 mM Tris-acetate, 1 mM EDTA) containing 0.5 μg/ml of ethidium bromide. EAV strains; B Bucyrus, mB modified Bucyrus, LV live vaccine, RM Red Mile, K 84 Y-A1, WR Wroclaw-2, BB Bibuna, V Vienna, M molecular weight marker φX174/Hae III digest, N no template

Each of the PCR products amplified using the M1-M14 primer was digested with each of the four restriction enzymes; Xba I, Mva I, Mbo II, and Alu I. Digestion of PCR products from the Bucyrus, modified Bucyrus, live vaccine, and Wroclaw-2 strains with Xba I gave rise to fragments of about 174 bp and 57 bp (Fig. 4a). Products from Red Mile and 84 KY-A1 digested with Mva I produced fragments of about 131 bp and 100 bp (Fig. 4b). Digestion of PCR products with Mbo II gave rise to fragments of about 200 bp and 31 bp in all strains except for the Wroclaw-2 and Vienna strains (Fig. 4c). The PCR products from all strains were cleaved by digestion with Alu I into two fragments of 164 bp and 67 bp. In Bibuna strain a 164 bp fragment was further cleaved into 110 bp and 54 bp fragments, allowing for three fragments of 110 bp, 67 bp and 54 bp to be produced (Fig. 4d). Of the PCR products using M6-M8 primer only PCR products derived from modified Bucyrus and the live vaccine were digested by Hha I, to give fragments of about 185 bp and 62 bp (Fig. 4e). PCR products from 84 KY-A1 and Red Mile strains were shown to share the same fragment patterns by the above 5 restriction enzymes. These strains were discriminated by digestion of PCR products using M9-M10 with Ava II, i.e. the digestion generated fragments of about 75 bp in all strains, plus fragments of about 56 bp and 110 bp in the Bucyrus, modified Bucyrus, live vaccine and Wroclaw-2 strains, about 94 bp and 72 bp in the Red Mile strain and about 166
Fig. 3. Nested PCR and its sensitivity in detecting EAV. A Analysis of the first round PCR products after amplification of ten-fold serially diluted culture fluid of cells infected with the modified Bucyrus EAV strain (2 x 10^7 PFU/ml) using the M1-M10 primer. B Analysis of the second round PCR products. The first round PCR products of each dilution were reamplified using each of the M1-M14, M6-M8, and M9-M10 inner primer sets. N no template, M molecular weight marker, EHV equine herpesvirus-1 DNA.

bp in the 84 KY-A1, Bibuna and Vienna strains (Fig. 4f). The results of the digestion of PCR products using M1-M14, M6-M8, and M9-M10, with the appropriate restriction enzymes, are summarized in Table 1. The Bucyrus, modified Bucyrus and live vaccine, the Red Mile and 84 KY-A1, and the Wroclaw-2, Bibuna and Vienna strains were differentiated by the digestion of PCR products using the M1-M14 primer with the four restriction enzymes XbaI, MvaI, MboII and AluI. The modified Bucyrus strain and live vaccine were discriminated from the others by the digestion of their PCR products using the M6-M8 primer with HhaI. AvaII digestion of PCR products using M9-M10 enabled us to distinguish between the Red Mile and 84 KY-A1 strains.

In PCR based detection systems for EAV, Chirnside et al. selected primer from the leader sequence, polymerase (ORF 1-b) and nucleocapsid gene (ORF 7)[4], and Belák et al. chose from the nucleocapsid gene [1]. We selected oligonucleotide
Fig. 4. Restriction enzyme analysis of PCR amplification products. PCR products using the primer pair M1-M14 (Fig. 2B) were digested with Xba I (a), Mva I (b) Mbo II (c), and Alu I (d). Product with the primer M6-8, (Fig. 2C) was digested with Hha I (e), and the primer M9-M10 (Fig. 2D) with Ava II (f). Ten µl of the final PCR products were digested in a 20 µl mixture containing 3 to 3.6 U of the restriction enzyme at 37 °C for an hour. Five µl of restriction enzyme digests were analyzed by electrophoresis on 3% agarose gel. Strains: B Bucyrus, mB modified Bucyrus, LV live vaccine, RM Red Mile, K 84 KY-A1, WR Wroclaw-2, BB Bibuna, V Vienna, M molecular weight marker φX174/Hae III digest, – no enzyme

primers from the ORF 6 gene because it has been shown to be an area with a higher sequence homology than ORF 7 among the members of the Arterivirus group [6, 16, 17]. We designed primer pairs so that there would be no mismatches or at most, a single base pair mismatch, and ensured that the area of amplification product contained the strain specific restriction site for the endonuclease.
Table 1. Differentiation of EAV strains by restriction enzyme analysis of PCR products

| Primers   | M1-M14 | M6-M8 | M9-M10 |
|-----------|--------|-------|--------|
| Enzyme    | Xba I  | Mva I | Mbo II |
| site³     | 1      | 2     | 1      |
| Bucyrus   | +      | -     | +      |
| m Bucyrus | +      | -     | +      |
| Live vaccine | +     | -     | +      |
| Red Mile  | -      | +     | +      |
| 84 KY-A1  | -      | +     | +      |
| Wroclaw   | -      | +     | -      |
| Bibuna    | -      | +     | +      |
| Vienna    | -      | -     | -      |

+ Cleaved at restriction site, – not cleaved

³ Alu I and Ava II have two and three cleavage sites in the PCR amplified region, respectively. Numbering the sites is from the 5’ terminal.

Recently, Chirnside et al. presented M and N gene sequences of 10 EAV isolates including the isolates used by us [5]. There were some differences in the M gene nucleotide sequence of Kentuncky 84 and Wroclaw-2 isolates from our data. If the restriction fragment length polymorphism (RFLP) patterns determined by the 6 restriction enzymes are assessed according to their nucleotide sequences, Pleural Fluid, MAFF Ireland, 185/83, NEA V2, Kentucky 84, and Wroclaw-2 isolates should show the same RFLP patterns as the Bucyrus isolate. These isolates exhibited a 96–98% nucleotide identity with Bucyrus isolate [5]. However, our RFLP patterns were exactly as predicted from our nucleotide sequence data.

In this paper we showed the RFLP patterns of single amplified PCR products from seven disparate strains using three sets of primers (Fig. 4). The same restriction enzyme patterns were also obtained by cutting the second round PCR products with restriction enzymes (data not shown).

Nested PCR and the restriction enzyme analysis of product can allow for the detection and identification of virus in small amounts of clinical samples. The live vaccine was provided after repeated passages of the modified Bucyrus strain in tissue culture. RNA from the live vaccine showed the same behavior in restriction enzyme digestion of PCR products as did the RNA from the modified Bucyrus virus. The restriction site of Hha I in the M6-M8 amplified area seems to be unique to the live vaccine, Arvac, and to the modified Bucyrus strains, according to our study and to reports by Chirnside et al. [5]. Fukunaga et al. demonstrated some serological differences between the modified Bucyrus strain and the Bucyrus, 84 KY-A1, and Wroclaw-2 strains using a serum cross neutralization test [10]. The differentiation between horses vaccinated with live vaccine and horses infected with wild strain should be reliable through RFLP analysis by using restriction sites from other ORFs, such as ORF 2, 4, and 5, in combination with serological differentiation using the neutralization. The application of PCR for EAV detection in clinical samples is presently under investigation.
References

1. Belák S, Ballagi-Pordány A, Timoney PJ, McCollum WH, Little TV, Hyllseth B, Klingeborn B (1994) Evaluation of a nested PCR assay for the detection of equine arteritis virus infection. Proceedings of the seventh international conference on equine infectious disease, Tokyo, 1994. R&W Publications, Newmarket, pp 33–38
2. Bürki F (1965) Eigenschaften des Virus der Equinen Arteritis. Pathol Microbiol 28:939–949
3. Bürki F (1970) The virology of equine arteritis. Proceedings of the 2nd international conference on equine infectious diseases, Paris 1969. Karger, Basel München New York, pp 125–129
4. Chirnside ED, Spaan WJM (1990) Reverse transcription and cDNA amplification by the polymerase chain reaction of equine arteritis virus (EAV). J Virol Methods 30:133–140
5. Chirnside ED, Wearing CM, Binns MM, Mumford JA (1994) Comparison of M and N gene sequences distinguishes variation amongst equine arteritis virus isolates. J Gen Virol 75:1491–1497
6. Conzelmann K-K, Visser N, van Woensel P, Thiel H-J (1993) Molecular characterization of porcine reproductive and respiratory syndrome virus, a member of the arterivirus group. Virology 193:329–339
7. den Boon JA, Snijder EJ, Chirnside ED, de Vries AAF, Horznik MC, Spaan WJM (1991) Equine arteritis virus is not a togavirus but belongs to the coronaviruslike superfamily. J Virol 65:2910–2920
8. Doll ER, Bryans JT, McCollum WH, Crowe MEW (1957) Isolation of a filterable agent causing arteritis of horses and abortion by mares. Its differentiation from the equine abortion (influenza) virus. Cornell Vet 47:3–41
9. Doll ER, Bryans JT, Wilson JC, McCollum WH (1968) Immunization against equine viral arteritis using modified live virus propagated in cell cultures of rabbit kidney. Cornell Vet 58:497–524
10. Fukunaga Y, Matsumura T, Sugiura T, Wada R, Imagawa H, Kanemaru T, Kamada M (1994) Use of the serum neutralisation test for equine viral arteritis with different virus strains. Vet Rec 134:574–576
11. Golnik W, Moraillon A, Golnik J (1986) Identification and antigenic comparison of equine arteritis virus: isolated from an outbreak of epidemic abortion of mares. J Vet Med B 33:413–417
12. Huntington PJ, Ellis PM, Forman AJ, Timoney PJ (1990) Equine viral arteritis. Aust Vet J 67:429–431
13. Kwok S, Kellogg DE, McKinney N, Spasic D, Goda L, Levenson C, Sninsky JJ (1990) Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies. Nucleic Acids Res 18:999–1005
14. McCollum WH (1969) Development of a modified virus strain and vaccine for equine viral arteritis. J Am Vet Med Assoc 155:318–322
15. McCollum WH, Swerczek TW (1978) Studies of an epizootic of equine viral arteritis in racehorses. J Equine Med Surg 2:293–299
16. Meng X-J, Paul PS, Halbur PG (1994) Molecular cloning and nucleotide sequencing of the 3′-terminal genomic RNA of the porcine reproductive and respiratory syndrome virus. J Gen Virol 75:1975–1801
17. Meulenberg JJM, Hulst MM, de Meijer EJ, Moonen PLJM, den Besten A, de Kuyver EP, Wensvoort G, Moormann RJM (1993) Lelystad virus, the causative agent of porcine epidemic abortion and respiratory syndrome (PEARS), is related to LDV and EAV. Virology 192:62–72
18. Mumford JA (1985) Preparing for equine arteritis. Equine Vet J 17:6–11
Detection and differentiation of EAV strains by PCR

19. Murphy TW, Timoney PJ, McCollum WH (1988) Analysis of genetic variation among strains of equine arteritis virus. Proceedings of the fifth international conference on equine infectious diseases, Lexington, 1987. University Press of Kentucky, Lexington, pp 3–12

20. Murphy TW, McCollum WH, Timoney PJ, Klingeborn BW, Hyllseth B, Golnik W, Erasmus B (1992) Genomic variability among globally distributed isolates of equine arteritis virus. Vet Microbiol 32: 101–115

21. Plagemann PGW, Moennig V (1992) Lactate dehydrogenase-elevating virus, equine arteritis virus, and simian hemorrhagic fever virus: a new group of positive-strand RNA viruses. Adv Virus Res 41: 99–192

22. Porterfield JS, Casals J, Chumakov MP, Gaidamovich SY, Hannoun C, Holmes IH, Horzinek MC, Mussgay M, Oker-Blom N, Russel PK, Trent DW (1978) Togaviridae. Intervirology 9: 129–148

23. Sugita S, Kondo T, Sekiguchi K, Yamaguchi S, Kamada M, Nerome K, Fukunaga Y (1994) Molecular evolution of equine arteritis virus. Proceedings of the seventh international conference on infectious diseases, Tokyo, 1994. R&W Publications, Newmarket, pp 39–43

24. Westaway EG, Brinton MA, Gaidamovich SY, Horzinek MC, Igarashi A, Kääriäinen L, Lvov DK, Porterfield JS, Russell PK, Trent DW (1984) Togaviridae. Intervirology 24: 125–139

25. Yamaguchi S, Kanno T, Inoue T, Sugita S, Fukunaga Y (1994) Sequence analysis of modified Bucyrus strain of equine arteritis virus. Proceedings of the seventh international conference on equine infectious diseases, Tokyo, 1994. R&W Publications, Newmarket, p 339

Authors’ address: Dr. K. Sekiguchi, Epizootic Research Station, Equine Research Institute, Japan Racing Association, 1400-4, Shiba, Kokubunji-Machi, Shimotsuga-Gun, Tochigi-Ken, 329-04, Japan.

Received January 25, 1995